Vanguard Capital Management
NEUP

Vanguard Capital Management’s Neuphoria Therapeutics NEUP Stock Holding History

Vanguard Capital Management’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$758K Buy
173,488
+74,972
+76% +$362K ﹤0.01% 3645
2026
Q1 		$401K Buy
+98,516
New +$416K ﹤0.01% 3710

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Vanguard Capital Management's NEUP Position: Q2 2026 in Review

Vanguard Capital Management increased its Neuphoria Therapeutics (NEUP) stake by 76% in Q2 2026, buying an estimated $362K and bringing the position to 173,488 shares worth $758K. The position accounts for ﹤0.01% of the portfolio, ranked #3645.

Vanguard Capital Management first reported a position in NEUP in Q1 2026 and has held it in 2 quarters since. 22 funds tracked by Wall St. Rank hold NEUP as of Q2 2026.

  • Vanguard Capital Management held 173,488 shares of Neuphoria Therapeutics worth $758K as of Q2 2026.
  • Vanguard Capital Management bought 74,972 Neuphoria Therapeutics shares in Q2 2026, an estimated $362K.
  • Neuphoria Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3645 holding.
  • Vanguard Capital Management first reported a position in Neuphoria Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 22 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.